Menu
GWAS Study

Genetic assessment of efficacy and safety profiles of coagulation cascade proteins identifies Factors II and XI as actionable anticoagulant targets.

Gagnon E, Girard A, Bourgault J et al.

38933427 PubMed ID
GWAS Study Type
891375 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

GE
Gagnon E
GA
Girard A
BJ
Bourgault J
AE
Abner E
GD
Gill D
TS
Thériault S
VM
Vohl MC
TA
Tchernof A
ET
Esko T
MP
Mathieu P
AB
Arsenault BJ
Chapter II

Abstract

Summary of the research findings

Aims: Anticoagulants are routinely used by millions of patients worldwide to prevent blood clots. Yet, problems with anticoagulant therapy remain, including a persistent and cumulative bleeding risk in patients undergoing prolonged anticoagulation. New safer anticoagulant targets are needed.

44,223 European ancestry cases, 847,152 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

891375
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Finland, U.K., Estonia
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.